Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2019 | Understanding the biology behind AML relapse

Charles Craddock • 5 Apr 2019
EBMT 2019
Acute Myeloid Leukemia Leukemia

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, from University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, talks about the importance of identifying the biological basis for acute myeloid leukemia (AML) relapse in developing effective maintenance strategies. This video was recorded at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Charles Craddock

Expanding donor access for allogeneic transplantation in AML
2:46
Expanding donor access for allogeneic transplantation in AML
Charles Craddock • 19 Sep 2026
Allogeneic transplantation in fit older adults with AML
1:34
Allogeneic transplantation in fit older adults with AML
Charles Craddock • 19 Sep 2026
Maximizing the graft-versus-leukemia effect after allogeneic transplantation in AML
1:35
Maximizing the graft-versus-leukemia effect after allogeneic transplantation in AML
Charles Craddock • 19 Sep 2026
Optimizing allogeneic transplantation through prospective randomized trials in AML
3:08
Optimizing allogeneic transplantation through prospective randomized trials in AML
Charles Craddock • 19 Sep 2026

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals